Drug intelligence / Profile preview

biomee IAD formulation

Development stage: Preclinical
Lead developer: MC2 Therapeutics
Modality: Small Molecules
Administration: Topical

Overview

Biomee IAD formulation is a topical skincare product developed by MC2 Therapeutics for the management of Incontinence-Associated Dermatitis (IAD). It utilizes the proprietary PAD Technology™, a delivery system that stabilizes oil-in-water dispersions to provide a non-greasy, moisturizing cream without the need for high concentrations of surfactants. The formulation is urea-based, designed to restore the skin barrier and provide essential hydration to skin areas affected by irritation and breakdown due to incontinence. By improving skin integrity and moisture levels, it aims to protect the skin from the damaging effects of prolonged exposure to moisture and irritants.

Brand names: biomee
Other names: biomee IADPAD Technology urea-based skincare - IAD formulation

Beyond the preview

Go deeper on biomee IAD formulation.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on biomee IAD formulation.

Explore the full profile